In a report released on April 15, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target of $70.00. The company’s shares closed yesterday at $51.79.
According to TipRanks, Singh Chadha is a 2-star analyst with an average return of -0.4% and a 42.05% success rate. Singh Chadha covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Boston Scientific, and Abbott Labs.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Globus Medical with a $64.89 average price target.
GMED market cap is currently $7.01B and has a P/E ratio of 44.47.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Globus Medical (GMED) Company Description:
Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.
Read More on GMED:
- Globus Medical Schedules First Quarter Earnings Release and Conference Call
- Globus Medical upgraded to Buy from Neutral at BTIG
- Globus Medical price target raised to $64 from $61 at Stifel
- Globus Medical backs FY24 EPS view $2.68 to $2.70, consensus $2.69
- Globus Medical reports Q4 EPS 60c, consensus 61c
